Vyscoxa is a drug owned by Carwin Pharmaceutical Associates Llc. It is protected by 1 US drug patent filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 17, 2045. Details of Vyscoxa's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12678405 | NA |
Sep, 2045
(18 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but
Vyscoxa is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Vyscoxa's family patents as well as insights into
ongoing legal events
on those patents.
Vyscoxa's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Vyscoxa:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Generic Launch
Generic Release Date:
Vyscoxa's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 17, 2045 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vyscoxa Generic API suppliers:
Celecoxib is the generic name for the brand Vyscoxa. 26 different companies have already filed for the generic of Vyscoxa, with Zydus Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Vyscoxa's generic
Alternative Brands for Vyscoxa
There are several other brand drugs using the same active ingredient (Celecoxib) as Vyscoxa. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Kowa Pharms |
| |
| Purple Biotech |
| |
| Scilex Pharms |
| |
| Upjohn |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Celecoxib, Vyscoxa's active ingredient. Check the complete list of approved generic manufacturers for Vyscoxa
About Vyscoxa
Vyscoxa is a drug owned by Carwin Pharmaceutical Associates Llc. Vyscoxa uses Celecoxib as an active ingredient. Vyscoxa was launched by Carwin Assoc in 2025.
Approval Date:
Vyscoxa was approved by FDA for market use on 29 July, 2025.
Active Ingredient:
Vyscoxa uses Celecoxib as the active ingredient. Check out other Drugs and Companies using Celecoxib ingredient
Dosage:
Vyscoxa is available in suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 10MG/ML | SUSPENSION | Prescription | ORAL |